Trials / Unknown
UnknownNCT04082507
Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta
Alpha-fetoprotein as a Biochemical Marker in Prediction of Placenta Acreta Increta Percreta
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- rasha medhat abdul-hady · Academic / Other
- Sex
- Female
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.
Detailed description
in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence of morbid adherent placenta accurately?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Serum alpha-fetoproteine | Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan . |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
- First posted
- 2019-09-09
- Last updated
- 2019-09-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04082507. Inclusion in this directory is not an endorsement.